Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyColorado Rocky Mountain Respiratory Update | OpenP…
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy CS379.C

    Respiratory Pathogen Nucleic Acid Detection Testing

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CS379.C alerts

    Get alerted when Policy CS379.C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of respiratory pathogen molecular testing, including multiplex nucleic acid amplification and metagenomic next-generation sequencing. In outpatient settings, respiratory pathogen panel testing that detects six or more targets is considered unproven and not medically necessary for all indications.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyRespiratory Pathogen Nucleic Acid Detection Testing
    Policy CodePolicy CS379.C
    Change TypeCoding revision
    Effective DateNov 1, 2026
    Next Review DateNot specified
    Key ActionOutpatient respiratory pathogen panel testing that detects six or more targets is considered unproven and not medically necessary due to insufficient evidence of efficacy for all indications.
    SourceLink
    POLICY UPDATE CHANGES

    The applicable CPT code list was updated to reflect quarterly edits.

    CPT code 0556U was removed from the applicable code list.

    6 or moreOutpatient panel target threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    85mNGS review studies
    9,414mNGS review individuals
    <30 minNear-patient testing turnaround

    Coverage Criteria

    Outpatient Respiratory Pathogen Panels of Six or More Targets

    Not medically necessary and unproven when all of the following apply:

    Outpatient broad respiratory pathogen panel

    • Respiratory pathogen panel testing is performed in an outpatient setting and detects six or more targets.6 or more targets

      Applies to all indications because evidence of efficacy is insufficient.

    FDA approval alone is not a basis for coverage. Coverage is determined under the policy’s medical-necessity criteria, regardless of FDA approval.

    Respiratory pathogen panel testing that detects six or more targets in an outpatient setting is considered not medically necessary for all indications because there is insufficient evidence of efficacy.

    Applicable Coding

    Applicable CodesCPT
    0115URespiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
    0202UInfectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
    0223UInfectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
    0225UInfectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
    0563UInfectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
    0564UInfectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
    87632Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
    87633Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
    FDA product codesmixed
    OCCFDA product code referenced for respiratory viral panel multiplex nucleic acid assay devices
    QDSFDA product code referenced for respiratory viral panel multiplex nucleic acid assay devices
    QDPFDA product code referenced for respiratory viral panel multiplex nucleic acid assay devices
    QOFFDA product code referenced for respiratory viral panel multiplex nucleic acid assay devices
    Removed applicable CPT codeCPT
    0556URemoved from the applicable CPT code list
    Respiratory Pathogen Panel Target Count
    Target thresholdSix or more targets
    Applicable settingOutpatient respiratory pathogen panel testing
    Coverage statusUnproven and not medically necessary due to insufficient evidence of efficacy for all indications

    Provider Action Required

    Denial Risk

    Six-or-more-target outpatient panels

    Outpatient respiratory pathogen panel testing that detects six or more targets is considered unproven and not medically necessary for all indications because evidence of efficacy is insufficient. Claims for these panels may be denied when performed in an outpatient setting.

    Clinical Background

    Respiratory pathogen molecular assays include reverse-transcription polymerase chain reaction (RT-PCR), other nucleic acid amplification tests, and metagenomic next-generation sequencing. Multiplex assays detect predefined microbial genetic material in respiratory specimens, while metagenomic sequencing is intended to detect genetic material from a broad range of organisms. Detection of microbial nucleic acid does not establish that a virus is viable or actively replicating. The policy identifies limited clinical utility for broad outpatient panels, including concerns about prolonged shedding, coinfections, variable test accuracy, and uncertain effects on individual outcomes.

    Testing Definitions

    Multiplex Reverse Transcription-Polymerase Chain Reaction Assay
    DefinitionA molecular assay that uses multiplex reverse transcription-polymerase chain reaction to identify predefined microbial genetic material in respiratory specimens, if present.
    Material detectedRNA or nucleic acids
    Detection approachIdentifies predefined microbial genetic material in respiratory specimens
    Metagenomic Next-Generation Sequencing
    DefinitionA sequencing approach that enables comprehensive detection of all genes from all organisms within a sample.
    Organisms detectedBacterial, fungal, parasitic, and viral pathogens

    Potentially Appropriate Testing Populations

    Hematology and Oncology Patients

    Multiplex respiratory viral panel testing may be appropriate for:

    ALL of the following

    • The patient is receiving care for a hematologic or oncologic condition.

      Identified in ASM practical guidance as a potentially appropriate population for testing.

    Transplant Patients

    Multiplex respiratory viral panel testing may be appropriate for:

    ALL of the following

    • The patient is a transplant recipient.

      Identified in ASM practical guidance as a potentially appropriate population for multiplex testing.

    Not Covered Services

    Respiratory pathogen panel testing that detects six or more targets in an outpatient setting is unproven and not medically necessary for all indications because of insufficient evidence of efficacy.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyRespiratory Pathogen Nucleic Acid Detection Testing
    Policy CodePolicy CS379.C
    Change TypeCoding revision
    Effective DateNov 1, 2026
    Next Review DateNot specified
    Key ActionOutpatient respiratory pathogen panel testing that detects six or more targets is considered unproven and not medically necessary due to insufficient evidence of efficacy for all indications.
    SourceLink
    On This Page
    Coverage CriteriaApplicable CodingProvider Action RequiredClinical BackgroundTesting DefinitionsPotentially Appropriate Testing PopulationsNot Covered Services
    Specimen scope
    Compares nucleic acid sequences extracted from a single tissue or liquid specimen

    Intensive Care Unit or Other Hospitalized Patients

    Comprehensive respiratory pathogen testing may be appropriate when:

    ALL of the following

    • ONE of

      • The patient is in an intensive care unit.

        ASM guidance identifies intensive care unit patients as potentially appropriate for respiratory viral multiplex panel testing.

      • The patient is hospitalized and comprehensive respiratory pathogen testing is needed to help guide appropriate antimicrobial therapy.

        IDSA guidance particularly supports comprehensive testing for hospitalized patients, especially those in intensive care units, when it can guide antimicrobial treatment.

    Pediatric Patients With an Underlying Illness

    Respiratory viral panel testing may be appropriate for:

    ALL of the following

    • The patient is a child with an underlying illness.

      Identified in ASM practical guidance as a potentially appropriate population for respiratory viral panel testing.

    Outpatients With Severe Respiratory Symptoms or High Risk for Complications

    In the outpatient setting, testing is recommended when either of the following applies:

    ONE of

    • The patient has severe respiratory symptoms.
    • ALL of the following

      • Examples include

        • The patient is older.
        • The patient is immunocompromised.